Emergent BioSolutions Inc.

As of June 30, 2026, Emergent BioSolutions Inc. carries a market capitalization of 436.56M, placing it among publicly traded companies globally. Its enterprise value stands at 878.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Emergent BioSolutions Inc.'s next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, Emergent BioSolutions Inc. has 51.30M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.60, and the price-to-book ratio stands at 1.28.

As of June 30, 2026, Emergent BioSolutions Inc. trades at an EV/EBITDA multiple of 30.94 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 878.66M versus a market cap of 436.56M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Emergent BioSolutions Inc. maintains a current ratio of 5.42, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 170.42, indicating elevated leverage, while an interest coverage ratio of 0.56 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Emergent BioSolutions Inc. posted a negative return on equity (ROE) of -40.29, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -13.95, reflecting losses generated across the asset base. The company generates approximately 824,777.78 in revenue per employee across its workforce of 900.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.06 indicates how many times Emergent BioSolutions Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Emergent BioSolutions Inc. recorded 30.80M in income tax expense. The company reported a pretax loss of -146.00M and -176.80M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Emergent BioSolutions Inc.'s stock has declined approximately 31.92% over the past 52 weeks. The 50-day moving average sits at 6.19, while the 200-day moving average is 8.29.

Over the twelve months ended June 30, 2026, Emergent BioSolutions Inc. generated 742.30M in revenue and converted that into -176.80M in net income, yielding earnings per share of -3.26. EBITDA reached 28.40M, while operating income came in at 137.50M.

As of June 30, 2026, Emergent BioSolutions Inc. holds 139.70M in cash and equivalents against 581.80M in total debt, resulting in a net debt position of 442.10M. Total book value stands at 341.40M, with working capital of 543.20M providing operational flexibility.

Emergent BioSolutions Inc. produced 97.70M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -11.80M in capital expenditures, free cash flow totaled 85.90M - equivalent to 1.64 per share.

Over the twelve months ended June 30, 2026, Emergent BioSolutions Inc. posted a gross margin of 54.21, reflecting its pricing power and cost economics. The operating margin of 18.52 and net profit margin of -23.82 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 18.61, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 37.93, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Emergent BioSolutions Inc. shareholders.

As of June 30, 2026, Emergent BioSolutions Inc. has an Altman Z-Score of 1.95, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.